US.MRK · Merck & Co.

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.0460610932475882,
        "turnoverUsdM": 961.0768312,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRK",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 116.8214,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.1,
      "take_profit_price": 130.62,
      "target_multiplier": 1.6,
      "technical_strength": 1.22,
      "take_profit_percent": 5
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.0921221864951765,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 52.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 125.0395,
    "ma50": 119.7398,
    "close": 124.4,
    "prevClose": 127.5,
    "avgVolume20": 10290660,
    "volumeRatio": 0.75,
    "changePercent": -2.43
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": 0.002983157324704999,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.6788566889460922,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.0888728540456063,
      "volat_points": 0,
      "day_range_pct": 0.029501607717041814,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 52.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 7,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 46.67,
        "contribution": 7
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 16.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 56.33,
        "contribution": 16.9
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 48.4,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 7/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 16.9/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 3.2,
      "資金流": 6.8,
      "市場環境": 7,
      "情緒分析": 2,
      "技術信號": 16.9,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.6,
          "debtPoints": 0.4,
          "marginPoints": 0.4,
          "turnoverUsdM": 961.0768312,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRK",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.77
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.11750425,
                "ma50": 719.0110022000002,
                "name": "QQQ",
                "close": 696.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.7885068500001,
                "ma50": 744.54560184,
                "name": "SPY",
                "close": 742.090027,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.0460610932475882,
          "atrPoints": 2,
          "cciPoints": 2.4,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140951734,
                "url": "https://finnhub.io/api/news?id=e94c351b9278c726bc71c4fbcb4d12cd2ea463aa8c1e8b53a845e6ed35f3f826",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck’s presence in cardiovascular medicine as key products approach patent expirations. Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years. The...",
                "category": "company",
                "datetime": 1784466405,
                "headline": "Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug"
              },
              {
                "id": 140934499,
                "url": "https://finnhub.io/api/news?id=50af81eacb5b348bfcee7acf2f5dcbee797ca7ede50b073747fb22c6b166afc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.",
                "category": "company",
                "datetime": 1784307000,
                "headline": "MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill"
              },
              {
                "id": 140922685,
                "url": "https://finnhub.io/api/news?id=2869bff87a1c06eb20ad3de55a0ea40ddca42c071348acd66bcf33a45ebabffa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck is back in focus as analysts refine their models, with bullish firms now setting price targets in a US$138 to US$155 range that sit above a refreshed fair value estimate of US$132.78 per share. These higher targets are being framed around updated earnings assumptions, views on the Q2 setup, and analysis of how Merck’s pipeline and regulatory backdrop could influence the stock’s risk and reward profile. Read on to see how to interpret these changing targets and follow the evolving Merck...",
                "category": "company",
                "datetime": 1784218352,
                "headline": "Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targets"
              },
              {
                "id": 140908305,
                "url": "https://finnhub.io/api/news?id=ab602b80101ae1ea410892ad9825017e121c9b1f3420dc8eb06f6abcba901c19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study. This is the first PD-1 inhibitor plus antibody drug conjugate regimen cleared for these patients regardless of cisplatin eligibility. The latest approval adds another indication for Merck's flagship oncology drug Keytruda. It reinforces the company’s presence in bladder...",
                "category": "company",
                "datetime": 1784118288,
                "headline": "Merck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer Use"
              },
              {
                "id": 140888430,
                "url": "https://finnhub.io/api/news?id=1878947d921411a7abc93a44daf05abd7d3b58271e42b8bb5bee329f2cdc7de1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.",
                "category": "company",
                "datetime": 1783955280,
                "headline": "FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer"
              },
              {
                "id": 140885871,
                "url": "https://finnhub.io/api/news?id=d281c232a9515f86e62357d878ab39deb1db50038740540ae1d56d022cad4a07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...",
                "category": "company",
                "datetime": 1783948141,
                "headline": "Merck (MRK) Stock Looks Like A Bargain At This Price"
              },
              {
                "id": 140882586,
                "url": "https://finnhub.io/api/news?id=dacd024657c409a5c498848e3ea460855a813613f3eaad4a724b245c2221a6c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”",
                "category": "company",
                "datetime": 1783906437,
                "headline": "Nasdaq, S&P 500, Dow Futures Fall After Trump Directs Strikes ‘To Hold Iranian Forces Accountable’: NVDA, SLS, MRK, SKHYV, QS Stocks In Focus"
              },
              {
                "id": 140866942,
                "url": "https://finnhub.io/api/news?id=67631bafdf38a6e424b16afae605f0c6073132b0aa502c97ab9d6a2ef2e274bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783719905,
                "headline": "Merck (MRK) Stock Sinks As Market Gains: Here's Why"
              }
            ],
            "raw_source": [
              {
                "id": 140962978,
                "url": "https://finnhub.io/api/news?id=02b2e30e4b5a8015da142e1b9a1f892637cc927d311f40cc472a5668f9bca33d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1784574604,
                "headline": "Stay informed with the top movers within the dow jones index on Monday."
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140963405,
                "url": "https://finnhub.io/api/news?id=953f03a95ac4369d23919084ddcefbfe8771f49595f8b6d1dbc914ca7cd2fca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784569523,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140965383,
                "url": "https://finnhub.io/api/news?id=252d2af92d35c827be0d28207193e18bcbf3b37d6beb9fe055e4471376919788",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Merck.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16,",
                "category": "company",
                "datetime": 1784567501,
                "headline": "Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio"
              },
              {
                "id": 140961420,
                "url": "https://finnhub.io/api/news?id=e613f9fe68ef0a1cdfe2f10691bd46234a818a12bfae7c5960dbd9c806ea565d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1784565604,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 140960660,
                "url": "https://finnhub.io/api/news?id=9e20055d766fed732707bbc04d0b1c9b6161557d859bc25479820765fa9dbf63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.",
                "category": "company",
                "datetime": 1784561412,
                "headline": "Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive"
              },
              {
                "id": 140965384,
                "url": "https://finnhub.io/api/news?id=33cc06c866f908274eff1bdb8e44b0db18ac0408518b07a78cfd2af42795a051",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Arcus-BioSciences.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.",
                "category": "company",
                "datetime": 1784558726,
                "headline": "Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?"
              },
              {
                "id": 140959510,
                "url": "https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784549820,
                "headline": "Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."
              },
              {
                "id": 140961123,
                "url": "https://finnhub.io/api/news?id=0617690bb008a2dddf3672e42d00cf7cdf55f63a846c07b0ff07f8f12209951c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2208146516/image_2208146516.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Eikon Therapeutics focuses on the development of solid tumor therapies. Read more on recent trials for this California-based biotech.",
                "category": "company",
                "datetime": 1784549100,
                "headline": "Eikon Therapeutics: Behind The Rough Debut"
              },
              {
                "id": 140958951,
                "url": "https://finnhub.io/api/news?id=5ed9acc8832a619e0dcafb8eca77d97a1e2404577fca62c7969d2a1bbc22ad55",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "ImmunityBio (IBRX) cautious buy: Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.",
                "category": "company",
                "datetime": 1784536225,
                "headline": "ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)"
              },
              {
                "id": 140957651,
                "url": "https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784527200,
                "headline": "What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."
              },
              {
                "id": 140951734,
                "url": "https://finnhub.io/api/news?id=e94c351b9278c726bc71c4fbcb4d12cd2ea463aa8c1e8b53a845e6ed35f3f826",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck’s presence in cardiovascular medicine as key products approach patent expirations. Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years. The...",
                "category": "company",
                "datetime": 1784466405,
                "headline": "Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140935746,
                "url": "https://finnhub.io/api/news?id=b8d366b0978045461c3e2f0f805013981ee50b4718778eb2469f0e71bb1d2514",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784315404,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 140934498,
                "url": "https://finnhub.io/api/news?id=d5e325853357032801312770e7b99a6265e4d99d76ac402f46ae2fcc455526af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?",
                "category": "company",
                "datetime": 1784307294,
                "headline": "Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move."
              },
              {
                "id": 140934499,
                "url": "https://finnhub.io/api/news?id=50af81eacb5b348bfcee7acf2f5dcbee797ca7ede50b073747fb22c6b166afc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.",
                "category": "company",
                "datetime": 1784307000,
                "headline": "MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill"
              },
              {
                "id": 140933705,
                "url": "https://finnhub.io/api/news?id=cf957e631b08afbc352ac0c9645261668019b12720ed7857cae855b3ae4f2250",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784306404,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140935932,
                "url": "https://finnhub.io/api/news?id=4bdbdb4a6e7a0da5a428929b1f9fcf9c2f9995f001fee97c8d0513a099568e28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285881217/image_2285881217.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. stock outlook: Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.",
                "category": "company",
                "datetime": 1784302236,
                "headline": "Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions"
              },
              {
                "id": 140932834,
                "url": "https://finnhub.io/api/news?id=78e5e8f079a9163c9983b838a804c3a1454e950919ff3b711da86ab6186281b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.",
                "category": "company",
                "datetime": 1784300733,
                "headline": "The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?"
              },
              {
                "id": 140934500,
                "url": "https://finnhub.io/api/news?id=b8d38ebc14f6fb86a9aaa49ca942ab31591c522f24a09a7b19d48899869a54d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.",
                "category": "company",
                "datetime": 1784300340,
                "headline": "MRNA Advances Cancer Pipeline With New Immunotherapy Study"
              },
              {
                "id": 140931621,
                "url": "https://finnhub.io/api/news?id=44ca6e27be05b8c4884145b2d473f5df1ed9c9f7af90663ee0d134eda5bc55f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.",
                "category": "company",
                "datetime": 1784295673,
                "headline": "Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies."
              },
              {
                "id": 140934501,
                "url": "https://finnhub.io/api/news?id=938601c3732c914a0c4dd0a88ace3c24c582e9e600b68d931e2fe659ed927630",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.",
                "category": "company",
                "datetime": 1784292034,
                "headline": "New Cholesterol Pill, Earnings Growth Boost Merck Shares"
              },
              {
                "id": 140930803,
                "url": "https://finnhub.io/api/news?id=704a99c54dff056d6fa420eece519f456857271973e6ff19825a3406a4e418aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.",
                "category": "company",
                "datetime": 1784284284,
                "headline": "MSD wins FDA approval for cholesterol pill to help plug Keytruda void"
              },
              {
                "id": 140934502,
                "url": "https://finnhub.io/api/news?id=c78d159a855366afde6c9753eae4bda31e77622cbdb6dbe8170468198da24a46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.",
                "category": "company",
                "datetime": 1784280100,
                "headline": "GSK shelves cough drug acquired in $2B deal"
              },
              {
                "id": 140927385,
                "url": "https://finnhub.io/api/news?id=9870d31d3feaa21dc79e1d3db77301012e5cd568a702190e29c45e6f44ff4234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Personalis has hired investment banks Centerview and TD Securities, along with law firm Cooley, to review its strategic options, according to a report in Street Insider.",
                "category": "company",
                "datetime": 1784244455,
                "headline": "Why Is PSNL Stock Up 5% After-Hours?"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140926127,
                "url": "https://finnhub.io/api/news?id=14070398601a23fcef12732bf9491310f80c3a8a0628d7f9f4fe04422bbf4057",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.",
                "category": "company",
                "datetime": 1784234703,
                "headline": "FDA approves first-of-its-kind cholesterol pill Lipfendra: What it will cost"
              },
              {
                "id": 140927352,
                "url": "https://finnhub.io/api/news?id=4167742add66fef57c25a1a3ec1f1df12211a8746213a22c8fcf36bdd9e9a214",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.",
                "category": "company",
                "datetime": 1784232612,
                "headline": "Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today"
              },
              {
                "id": 140923898,
                "url": "https://finnhub.io/api/news?id=0599a730d1c9c8a1c033764e0e99b20ef3fc7cc5b00c7e3e5a714468a2ea583b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1784229003,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 140922685,
                "url": "https://finnhub.io/api/news?id=2869bff87a1c06eb20ad3de55a0ea40ddca42c071348acd66bcf33a45ebabffa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck is back in focus as analysts refine their models, with bullish firms now setting price targets in a US$138 to US$155 range that sit above a refreshed fair value estimate of US$132.78 per share. These higher targets are being framed around updated earnings assumptions, views on the Q2 setup, and analysis of how Merck’s pipeline and regulatory backdrop could influence the stock’s risk and reward profile. Read on to see how to interpret these changing targets and follow the evolving Merck...",
                "category": "company",
                "datetime": 1784218352,
                "headline": "Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targets"
              },
              {
                "id": 140921022,
                "url": "https://finnhub.io/api/news?id=316d2c37caa54647b8c49f90a5264d54f99be94b943b3efadcd5cf31638afaea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) is approaching key pipeline catalysts with ISLEND and islatravir plus ulonivirine data t",
                "category": "company",
                "datetime": 1784216405,
                "headline": "Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says"
              },
              {
                "id": 140921023,
                "url": "https://finnhub.io/api/news?id=c841521090eb2d0487f8096cf5c42fe77514039d13a26ba38fdbc226aa19cbce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.",
                "category": "company",
                "datetime": 1784216357,
                "headline": "Merck Snags A First-Of-Its-Kind Approval, And Shares Jump"
              },
              {
                "id": 140934851,
                "url": "https://finnhub.io/api/news?id=7d86a54799add3daf2c7f18b51bf3b79f4f675bff1404bf141b4db9acd56f135",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.",
                "category": "company",
                "datetime": 1784212876,
                "headline": "FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919808,
                "url": "https://finnhub.io/api/news?id=9f49b8a6e7640a41f99b1c8bfc28e099d45c10878a320d2650880060055de93e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.",
                "category": "company",
                "datetime": 1784207534,
                "headline": "Dow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumps"
              },
              {
                "id": 140919720,
                "url": "https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.",
                "category": "company",
                "datetime": 1784205864,
                "headline": "Why Is The Market Punishing JNJ Stock?"
              },
              {
                "id": 140921681,
                "url": "https://finnhub.io/api/news?id=3d6b88aa16f27ea2466e52cf5ac477ead380ed462ce56fc41c2e4583fae31688",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175574079/image_2175574079.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "SCHD is beating the S&P 500 with a 3.2%+ yield, low beta and defensive sector mix. Learn more about SCHD ETF here.",
                "category": "company",
                "datetime": 1784204843,
                "headline": "SCHD: Your ETF To Hide From The AI Bottleneck Bust"
              },
              {
                "id": 140919810,
                "url": "https://finnhub.io/api/news?id=fd63bcbaec4bc9f09b2e7674a9fd7fc7a2ddcf1c2cebdcf2149ebe4fff70e54b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck Opens BioReliance® Testing Facility in Darmstadt, Germany The facility expands access to commercial drug substance and drug product release testing as well as stability testing for biopharmaceutical companies developing and commercializing therapies in Europe. Darmstadt, Germany, July 16, 2026 (GLOBE NEWSWIRE) -- New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing and GMP-compliant stability studiesStrategic",
                "category": "company",
                "datetime": 1784204400,
                "headline": "Merck Opens BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe"
              },
              {
                "id": 140919811,
                "url": "https://finnhub.io/api/news?id=12d3e8fb22281e211a912d0e9096c6e537c6d8e683867a1bce697f16ecc10d27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.",
                "category": "company",
                "datetime": 1784204220,
                "headline": "Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill"
              },
              {
                "id": 140918862,
                "url": "https://finnhub.io/api/news?id=6170f268e1d50a5a8f028cecb036f101fda0203236ea07c273e2563fa4049208",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 16, 2026--Merck’s LIPFENDRA is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia",
                "category": "company",
                "datetime": 1784198700,
                "headline": "Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia"
              },
              {
                "id": 140918861,
                "url": "https://finnhub.io/api/news?id=7877303fb718b2579c613cce560673cb9c26ae710beefbc833cb3e4474640c02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.",
                "category": "company",
                "datetime": 1784198700,
                "headline": "Merck Gets Approval for Powerful Cholesterol-Cutting Pill"
              },
              {
                "id": 140919812,
                "url": "https://finnhub.io/api/news?id=4f9a2c0d79fbf244840c0bcdf35a0bcea5be8a3b514cf0a1f26f039482e4ef99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.",
                "category": "company",
                "datetime": 1784193720,
                "headline": "Merck wins first approval of a PCSK9 cholesterol pill"
              },
              {
                "id": 140922148,
                "url": "https://finnhub.io/api/news?id=4c83505cb55e39a788e69d9c3fb67029d5d170d1e07d86a9410cc2a237477d2a",
                "image": "https://image.cnbcfm.com/api/v1/image/108335869-17842002661784200239-47196619443-1080pnbcnews.jpg?v=1784200265&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Angelica Peebles reports on the latest news on Eli Lilly.",
                "category": "company",
                "datetime": 1784187404,
                "headline": "Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion"
              },
              {
                "id": 140920454,
                "url": "https://finnhub.io/api/news?id=f6af621bfd2ddc0b7333cdf42bac1f4c3aa520f2aac5f3ee1ce42c464ca434c9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectivelyLIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and",
                "category": "company",
                "datetime": 1784184398,
                "headline": "Merck Says FDA Approves LIPFENDRA Tablets 20 Mg As Adjunct To Diet And Exercise To Reduce Low-Density Lipoprotein Cholesterol In Adults With Hypercholesterolemia"
              },
              {
                "id": 140912443,
                "url": "https://finnhub.io/api/news?id=6750508196e401c3e7147c7d16e101bbbf6a7f4a57e20206b50542adf6290ea5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1784142603,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140911186,
                "url": "https://finnhub.io/api/news?id=d2612052d9f84c92d994a744608379e467802d35adcdb495958f835110241182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.",
                "category": "company",
                "datetime": 1784136544,
                "headline": "Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price"
              },
              {
                "id": 140910530,
                "url": "https://finnhub.io/api/news?id=d3f52428a05de534ed0291c48948492f6aadc30b433f1701d5322f7b8d1fb595",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784133603,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140909679,
                "url": "https://finnhub.io/api/news?id=37baedc8006d55f0fb3eab4c3b82342685c7d228919d9f82f419fefd151676f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock popped Wednesday on the back of positive test results for a new treatment combo in a common form of lung cancer.",
                "category": "company",
                "datetime": 1784129296,
                "headline": "Can Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer?"
              },
              {
                "id": 140908291,
                "url": "https://finnhub.io/api/news?id=0d0624a838561883cccbce2049c90946462af750bb8835a9588f37dbafa0c70e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Stock Market Today: The Dow Jones index rose Wednesday after a cool inflation reading. ASML stock jumped on earnings.",
                "category": "company",
                "datetime": 1784123034,
                "headline": "Stock Market Today: Dow Rises On Surprise Inflation Data; ASML Jumps On Earnings Report (Live Coverage)"
              },
              {
                "id": 140908302,
                "url": "https://finnhub.io/api/news?id=f785a551a475678be8a6db4d249d894ee9b7f4e9bccdffcb34233f6b6a46aac4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock popped Wednesday on the back of positive test results for a new treatment combo in a common form of lung cancer.",
                "category": "company",
                "datetime": 1784122701,
                "headline": "Dow Jones' Merck Scores A Win With Cancer Smart Bomb"
              },
              {
                "id": 140912168,
                "url": "https://finnhub.io/api/news?id=3abd37f24c280e8691f319fff91354bbe5e172310610285edaf033a44c28bfc6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Merck.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemotherapy in advanced endometrial cancer.",
                "category": "company",
                "datetime": 1784121915,
                "headline": "Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer"
              },
              {
                "id": 140908133,
                "url": "https://finnhub.io/api/news?id=480ecd1efdac3a227829eb7883cc5a86f40c88e0b34b3e5bcfe8c909920a0c06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1784120409,
                "headline": "Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"
              },
              {
                "id": 140908304,
                "url": "https://finnhub.io/api/news?id=e84d927720a51cda0f5647a9b81ded49e0fe6c19ff9fdd33530698e4b583f60b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1%, and the actively tra",
                "category": "company",
                "datetime": 1784119985,
                "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Economic Reports"
              },
              {
                "id": 140907857,
                "url": "https://finnhub.io/api/news?id=c6c9fadccd35ba1fed87eb33657c5d3e74fc3bd0010caa0c3e6a9e822474a0f5",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.",
                "category": "company",
                "datetime": 1784118901,
                "headline": "Get insights into the top movers in the S&P500 index of Wednesday's pre-market session."
              },
              {
                "id": 140908305,
                "url": "https://finnhub.io/api/news?id=ab602b80101ae1ea410892ad9825017e121c9b1f3420dc8eb06f6abcba901c19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study. This is the first PD-1 inhibitor plus antibody drug conjugate regimen cleared for these patients regardless of cisplatin eligibility. The latest approval adds another indication for Merck's flagship oncology drug Keytruda. It reinforces the company’s presence in bladder...",
                "category": "company",
                "datetime": 1784118288,
                "headline": "Merck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer Use"
              },
              {
                "id": 140908306,
                "url": "https://finnhub.io/api/news?id=30cb69bc333da5478e214461d6ca7ce58f0b6cbb1ba1d1e6d4307da2108e7233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RALEIGH, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- Slate Medicines (Slate), a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, today announced the appointment of Mark W. Hahn to the company's Board of Directors. Mr. Hahn brings more than 25 years of leadership experience building and scaling life sciences companies. \"We are pleased to welcome Mark to the Slate Medicines Board at such a pivotal moment for the company,\" said Gregory Oak",
                "category": "company",
                "datetime": 1784116800,
                "headline": "Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn"
              },
              {
                "id": 140909680,
                "url": "https://finnhub.io/api/news?id=a882faaba7a39ab10a6977b3cd90591c84e373c19d2dc87e940dc39b5a24cde9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.",
                "category": "company",
                "datetime": 1784115660,
                "headline": "Merck ADC, in China study, shows potential to replace chemo in lung cancer"
              },
              {
                "id": 140907475,
                "url": "https://finnhub.io/api/news?id=6dcd0d28f46044da0cddbf0182e9892701bc4685881a7a2414e7d68cfb50418c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 15, 2026--Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026",
                "category": "company",
                "datetime": 1784113200,
                "headline": "Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026"
              },
              {
                "id": 140907476,
                "url": "https://finnhub.io/api/news?id=b8a991b2e01c86b56dc98c0f4ac6c3e2fdc1b95d61544ec5ddd62fcfb116cbcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 15, 2026--KEYTRUDA as Monotherapy Significantly Improved PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer Compared to Chemotherapy",
                "category": "company",
                "datetime": 1784112300,
                "headline": "KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy"
              },
              {
                "id": 140912169,
                "url": "https://finnhub.io/api/news?id=5115b129012d8df967b5193e67b24c3563d9ddce6836d8bf905bfd94de7b2cc9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of",
                "category": "company",
                "datetime": 1784098111,
                "headline": "Merck's Phase 3 KEYNOTE‑C93 Trial Evaluating KEYTRUDA Met Primary Endpoint Of Progression-Free Survival For Treatment Of Patients With Mismatch Repair Deficient Advanced Or Recurrent Endometrial Cancer"
              },
              {
                "id": 140901110,
                "url": "https://finnhub.io/api/news?id=a418695849289d29baabb02fccad0cc1323fa81f759a05f46d8ec554e1e50864",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1784056204,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140899749,
                "url": "https://finnhub.io/api/news?id=84094e3225d70c38db6c6d50a9e1c231ea6494cc942138536531dc77bf34a499",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.",
                "category": "company",
                "datetime": 1784046620,
                "headline": "This Healthcare Giant Still Checks Every Box for Long-Term Investors"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140900776,
                "url": "https://finnhub.io/api/news?id=472ffc9e1c34527f50c19adb2c3e53aab6255066151051c2bc57b056856451e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237287346/image_2237287346.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. Read more on SLS stock here.",
                "category": "company",
                "datetime": 1784041616,
                "headline": "SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up"
              },
              {
                "id": 140898076,
                "url": "https://finnhub.io/api/news?id=f40aa289b2dde6583d36a61262e45aaeea6e34024e49b68b4911c34191600fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.",
                "category": "company",
                "datetime": 1784039400,
                "headline": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results"
              },
              {
                "id": 140898155,
                "url": "https://finnhub.io/api/news?id=6d4a33b47289f081e1decf603f5fe621103805f6f365d34500b2ac909e8a981c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.",
                "category": "company",
                "datetime": 1784037180,
                "headline": "Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?"
              },
              {
                "id": 140901522,
                "url": "https://finnhub.io/api/news?id=329dad206b26f18b6eb7034fd88d2e6909c2fbf288a547a9be1da75eeadf9637",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.",
                "category": "company",
                "datetime": 1784031042,
                "headline": "Earnings Preview: What To Expect From Merck & Co.'s Report"
              },
              {
                "id": 140889976,
                "url": "https://finnhub.io/api/news?id=853634e3215adae0307c8aa5ba126a884c266f5f82638bd677c0b4bb959be1c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.",
                "category": "company",
                "datetime": 1783965635,
                "headline": "Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140888429,
                "url": "https://finnhub.io/api/news?id=13d6e4cd62b132435b52aa56bea0e9b4f7d918437b7a994997501f8c73faa29a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in GreeceFive-year agreement expected to contribute to revenue and cash-flow visibilityAs a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reachDIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022Po",
                "category": "company",
                "datetime": 1783962000,
                "headline": "Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece"
              },
              {
                "id": 140888430,
                "url": "https://finnhub.io/api/news?id=1878947d921411a7abc93a44daf05abd7d3b58271e42b8bb5bee329f2cdc7de1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.",
                "category": "company",
                "datetime": 1783955280,
                "headline": "FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140885871,
                "url": "https://finnhub.io/api/news?id=d281c232a9515f86e62357d878ab39deb1db50038740540ae1d56d022cad4a07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...",
                "category": "company",
                "datetime": 1783948141,
                "headline": "Merck (MRK) Stock Looks Like A Bargain At This Price"
              },
              {
                "id": 140885872,
                "url": "https://finnhub.io/api/news?id=5278afd659ead48962f28b4c7f7426a6ba09e432440e8ca3612e6986e3a72192",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026",
                "category": "company",
                "datetime": 1783944000,
                "headline": "Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004"
              },
              {
                "id": 140891097,
                "url": "https://finnhub.io/api/news?id=295cbdd3d345947d66f72242e33afe416d280d034c34dccdf44f3c75ccab4725",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "JP Morgan  analyst Chris Schott   maintains Merck &amp; Co (NYSE:MRK) with a Overweight and raises the price target from $135 to $140.",
                "category": "company",
                "datetime": 1783942998,
                "headline": "JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $140"
              },
              {
                "id": 140891098,
                "url": "https://finnhub.io/api/news?id=0c0f26bdc8ff5c2de071dcd765e06610e0c18b692931d25fb4618b4459ace900",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "BMO Capital  analyst Evan David Seigerman   maintains Merck &amp; Co (NYSE:MRK) with a Outperform and raises the price target from $135 to $142.",
                "category": "company",
                "datetime": 1783933123,
                "headline": "BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $142"
              },
              {
                "id": 140891099,
                "url": "https://finnhub.io/api/news?id=27bf2228e7a7e222be0d3ef3d3e7d164c856b60ef1554a9c7d45974efe7de02d",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Merck &amp; Co (NYSE:MRK) with a Buy and raises the price target from $140 to $145.",
                "category": "company",
                "datetime": 1783932000,
                "headline": "Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $145"
              },
              {
                "id": 140891100,
                "url": "https://finnhub.io/api/news?id=7deb3e439675b7d7a8298846a5863b276e19d71034129faf29754996c441be9d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Merck-Chooses-Switzerland.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck &amp; Co. shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.",
                "category": "company",
                "datetime": 1783930839,
                "headline": "Why Merck Stock Is in the Spotlight Today"
              },
              {
                "id": 140883027,
                "url": "https://finnhub.io/api/news?id=b44474c02fa172be73c1ab8b2c5b47a46b91d9a1e114148076ce91583e08715e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.",
                "category": "company",
                "datetime": 1783910910,
                "headline": "SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears"
              },
              {
                "id": 140882586,
                "url": "https://finnhub.io/api/news?id=dacd024657c409a5c498848e3ea460855a813613f3eaad4a724b245c2221a6c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”",
                "category": "company",
                "datetime": 1783906437,
                "headline": "Nasdaq, S&P 500, Dow Futures Fall After Trump Directs Strikes ‘To Hold Iranian Forces Accountable’: NVDA, SLS, MRK, SKHYV, QS Stocks In Focus"
              },
              {
                "id": 140866942,
                "url": "https://finnhub.io/api/news?id=67631bafdf38a6e424b16afae605f0c6073132b0aa502c97ab9d6a2ef2e274bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783719905,
                "headline": "Merck (MRK) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 140865338,
                "url": "https://finnhub.io/api/news?id=d9b3d4cd98409619ec0c5882fdbae7aa759d05b52654942e444b7f2574d8fe0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 10, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck’s anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bladde",
                "category": "company",
                "datetime": 1783707000,
                "headline": "FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)"
              },
              {
                "id": 140863713,
                "url": "https://finnhub.io/api/news?id=f1b2c2cebd6715831501571f2e0eaa6df6e4dbd5dd50cb7f5e5c18fd5cf66369",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Friday.",
                "category": "company",
                "datetime": 1783701603,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 140861555,
                "url": "https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.",
                "category": "company",
                "datetime": 1783684953,
                "headline": "JNJ Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 140873796,
                "url": "https://finnhub.io/api/news?id=0834007187294a8053c5d6a0363f926567aaeaf14150e2b0570182de30af9b82",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin",
                "category": "company",
                "datetime": 1783680561,
                "headline": "FDA Approves Pembrolizumab Or Pembrolizumab And Berahyaluronidase Alfa-pmph Each With Enfortumab Vedotin-ejfv For Muscle Invasive Bladder Cancer"
              },
              {
                "id": 140858499,
                "url": "https://finnhub.io/api/news?id=ff62adc1f5e4e9e24af6163944e028e2aa4af7750f6f1d35af5cd06ac29fb9ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.",
                "category": "company",
                "datetime": 1783639802,
                "headline": "This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026"
              },
              {
                "id": 140854740,
                "url": "https://finnhub.io/api/news?id=f01e0b0e06127f9e5fd58bae5a86a0425327da12f5e1693b13c85b4dd00602d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.",
                "category": "company",
                "datetime": 1783621260,
                "headline": "EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?"
              },
              {
                "id": 140853541,
                "url": "https://finnhub.io/api/news?id=9a62fecb6a6ef6aed8786ef4f4918bf9259eb119c510f5913306141e4b4334e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key opportunities in the Southeast Asia oncology drug access market involve prioritizing accessibility, affordability, and availability of therapies through government initiatives, biosimilar adoption, and patient assistance programs. Collaboration among stakeholders enhances access to innovative treatments, while advancements in precision oncology drive growth, despite challenges like high costs and regulatory complexities.Dublin, July 09, 2026 (GLOBE NEWSWIRE) -- The \"Southeast Asia Oncology D",
                "category": "company",
                "datetime": 1783612380,
                "headline": "Southeast Asia Oncology Drug Access Market Now Available; Profiles Roche, AstraZeneca, Merck, and Other Key Peers"
              },
              {
                "id": 140852126,
                "url": "https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.",
                "category": "company",
                "datetime": 1783609118,
                "headline": "Make Your AMGN Shares Pay You 8.7% While You Hold Them"
              },
              {
                "id": 140862237,
                "url": "https://finnhub.io/api/news?id=4b7955e8a026bc3a0e050b7dd7695262c9d1ae69b00a6ccc30afeae331b3ce89",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Merck &amp; Co (NYSE:MRK) with a Equal-Weight and raises the price target from $112 to $113.",
                "category": "company",
                "datetime": 1783603109,
                "headline": "Morgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $113"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140852182,
                "url": "https://finnhub.io/api/news?id=44e3f9e8461045391c4a83bc13f1bc62e5628bbd2f31024755d11d0d0b36d472",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783602006,
                "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140851673,
                "url": "https://finnhub.io/api/news?id=e2e9434a4678dfc4b99977f73b96b17f95ea6c8f42841d8dcffe450c72dc44d8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/09/Dallas--Tx---August-5--2022-Senator-Rick.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Scott urges Trump admin to increase tariffs on Chinese generic drug makers, citing forced labor &amp; safety concerns. Calls for accountability.",
                "category": "company",
                "datetime": 1783572093,
                "headline": "Rick Scott Urges Trump to Increase Tariffs on Chinese Generic Drug Makers Over 'Uyghur Slave Labor' Claims"
              },
              {
                "id": 140846351,
                "url": "https://finnhub.io/api/news?id=f04de45506b1a90b3aaccb38d94091579d0f7a89baec41e482f1e15044ce0b0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has reached a new access agreement with the ADAP Crisis Task Force for its once daily HIV treatment IDVYNSO. This development gives investors fresh context for assessing the stock. See our latest analysis for Merck. Merck shares recently pulled back, with a 1-day share price return declining 2.23% to close at US$125.99. However, the 30-day share price return of 5.41% and 1-year total shareholder return of 55.54% point to momentum that remains broadly positive. If Merck’s recent...",
                "category": "company",
                "datetime": 1783548990,
                "headline": "Merck (MRK) Gets New HIV Access Deal As Its Valuation Narrative Stays In Focus"
              },
              {
                "id": 140845513,
                "url": "https://finnhub.io/api/news?id=549a6b89bc122af3450e9e6b2e9dafa75bced723502ae900d2404bf032669cec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX plus Trodelvy for first-line PD-L1–positive advanced triple-negative breast cancer and EU approval of KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. These approvals further entrench KEYTRUDA at the center of Merck’s cancer portfolio, broadening its use across hard-to-treat tumors while the company prepares for future loss of...",
                "category": "company",
                "datetime": 1783545346,
                "headline": "Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?"
              },
              {
                "id": 140845480,
                "url": "https://finnhub.io/api/news?id=cad5ed53bd8a2b4b54d307f8fa766bc06c0d53359b5fdc9884250cb3c2debfec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Tesla, Bank of America and Merck lead today's featured research, highlighting growth drivers, risks and outlooks shaping these widely watched stocks.",
                "category": "company",
                "datetime": 1783542540,
                "headline": "Top Research Reports for Tesla, Bank of America & Merck"
              },
              {
                "id": 140844401,
                "url": "https://finnhub.io/api/news?id=1e6f7b15e160167e71834984cc3c9da524bf2f444e60c4777d8c0607565d09f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The chipmaker signaled a major turn in its business, and the market bought it. Now comes the hard part: proving the rally can last.",
                "category": "company",
                "datetime": 1783535858,
                "headline": "Texas Instruments Stock Is Running On A Bold Promise"
              },
              {
                "id": 140843423,
                "url": "https://finnhub.io/api/news?id=2702b66ac2ac5c03c36756010c05b66cc8e79917f95f9b0300663e0c8fe0c4a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "By Karen Roman Redwire Corporation (NYSE: RDW) said it designated Paul Reichert and Niki Werkheiser to serve at strategic advisory roles at Space Microgravity Development (SpaceMD), Redwire’s venture company focused […]",
                "category": "company",
                "datetime": 1783530982,
                "headline": "Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds"
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140840493,
                "url": "https://finnhub.io/api/news?id=684da8d2a4e5f5ee2cdba89a999ca639b2c146877af8d6e1d7fb5e72a1957ecb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.",
                "category": "company",
                "datetime": 1783513500,
                "headline": "MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?"
              },
              {
                "id": 140839611,
                "url": "https://finnhub.io/api/news?id=aa1b4335fc7f96b4f86da9d5bd3b6e46b4e6fb934699e65c033594c66b519837",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "JACKSONVILLE, Fla., July 08, 2026--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principal Investigator at Merck Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, to serve in strategic advisory roles at Space Microgravity Development LLC (SpaceMD), Redwire’s venture company focused o",
                "category": "company",
                "datetime": 1783508400,
                "headline": "Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities"
              },
              {
                "id": 140846132,
                "url": "https://finnhub.io/api/news?id=219d003d42a175c0c2d370c0eaf041a94b7de499a8353c7b6222a81d8d1b01de",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "RBC Capital  analyst Trung Huynh   reiterates Merck &amp; Co (NYSE:MRK) with a Outperform and maintains $142 price target.",
                "category": "company",
                "datetime": 1783504236,
                "headline": "RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target"
              },
              {
                "id": 140840980,
                "url": "https://finnhub.io/api/news?id=f6b89872007a09af68ad6c31154624cb9a96d205fade79b74bd2350ac6679dce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/08/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay&#39;s cut T PT to $24, MS cut ROL PT to $65, GS cut SAM PT to $169, BofA raised ALLY PT to $53, Citi raised EW PT to $110, Wells Fargo raised MRK PT to $150, Jefferies raised ENVA PT.",
                "category": "company",
                "datetime": 1783500020,
                "headline": "Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday"
              },
              {
                "id": 140846134,
                "url": "https://finnhub.io/api/news?id=fb1f3b42e8de991b4bd303aac18ec1763330d32a0b0ad31f39955562dafe8bbf",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Merck &amp; Co (NYSE:MRK) with a Overweight and raises the price target from $145 to $150.",
                "category": "company",
                "datetime": 1783492914,
                "headline": "Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $150"
              },
              {
                "id": 140830563,
                "url": "https://finnhub.io/api/news?id=db2174c073837831286ca2c07c1b3b00b29ddae31ee4aaebfa28b835704e34e6",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1783420110,
                "headline": "SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn"
              },
              {
                "id": 140830044,
                "url": "https://finnhub.io/api/news?id=a525b2f107ac14ff07317a5d0fd2a984f07cf0426b0135b325b8d65da9b43696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.",
                "category": "company",
                "datetime": 1783413771,
                "headline": "Can anyone catch up to Eli Lilly?"
              },
              {
                "id": 140825364,
                "url": "https://finnhub.io/api/news?id=3462254cc01a429463310b2473d7a1b5e4b5e87bc51e87c16d916a740ef0bc24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.",
                "category": "company",
                "datetime": 1783374605,
                "headline": "Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140824128,
                "url": "https://finnhub.io/api/news?id=755bfac8086b55458ed003b38133dd776e18096e6e6946c3c4a4bc64ae17e627",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.",
                "category": "company",
                "datetime": 1783371901,
                "headline": "Which S&P500 stocks are showing activity after the closing bell on Monday?"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140823275,
                "url": "https://finnhub.io/api/news?id=aacc08c69cab6b9db8a0b9bbabb6718315106d78c1d7f115fc1eb8077d774c13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Monday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1783365003,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 140823501,
                "url": "https://finnhub.io/api/news?id=ea549e3b52e2e94af16a616297f7a713296a52a22cf774b483df1bb0afc662c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index fell but other indexes rallied as President Trump made bullish comments. Microsoft fell on the stock market today while Micron rose.",
                "category": "company",
                "datetime": 1783364029,
                "headline": "Stock Market Today: Dow Up, AI Stock Tests Entry; TeraWulf Cedes Key Level Despite Anthropic Deal (Live Coverage)"
              },
              {
                "id": 140823613,
                "url": "https://finnhub.io/api/news?id=6b219e38084e6475784ec645d74c2fa22bed3720375dabbf7ff1d4559a279cdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.",
                "category": "company",
                "datetime": 1783362960,
                "headline": "Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?"
              },
              {
                "id": 140821033,
                "url": "https://finnhub.io/api/news?id=4c61cc364714533bd4f04c0f59c93534543bbcf3cc26ac7b0713b270e8efaada",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.",
                "category": "company",
                "datetime": 1783352496,
                "headline": "Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings"
              },
              {
                "id": 140824936,
                "url": "https://finnhub.io/api/news?id=89bd33c0e677d2320cedd19adf8992de1bb1e9b573a15c20c0d361d0e1d5ffa6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV &amp; oncology potential.",
                "category": "company",
                "datetime": 1783346723,
                "headline": "Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says"
              },
              {
                "id": 140824618,
                "url": "https://finnhub.io/api/news?id=1cd268edbc835f22e1ed85b0dc0df50fb53a9d0098a14558c26e1aa4b1f18494",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783344935,
                "headline": "8 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140818670,
                "url": "https://finnhub.io/api/news?id=5bb378871c4d7250110c755b530ad54ad40bcf2da5fe3ace6f349cc9076ef393",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_48_b0208efde3.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Thursday's jobs report came in far below forecasts, initially easing pressure on the Federal Reserve, before a fresh slide in memory and semiconductor stocks dragged the Nasdaq lower even as the Dow closed at a record. Tesla sold off despite its best delivery quarter in years, healthcare names caught a bid, and SK Hynix lined up what would be the largest US listing ever by a foreign company.",
                "category": "company",
                "datetime": 1783331949,
                "headline": "Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway."
              },
              {
                "id": 140824938,
                "url": "https://finnhub.io/api/news?id=92921093c423eb00b73c135e6be39d773b9285a26371027163ca311cdc2c9177",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Merck &amp; Co (NYSE:MRK) with a Neutral and maintains $120 price target.",
                "category": "company",
                "datetime": 1783329296,
                "headline": "Cantor Fitzgerald Reiterates Neutral on Merck & Co, Maintains $120 Price Target"
              },
              {
                "id": 140814545,
                "url": "https://finnhub.io/api/news?id=7762ea644fb03778da654b93f7dfa933d7c1234ba00dfef0d0d4b7426470cfe5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to ... Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year",
                "category": "company",
                "datetime": 1783273647,
                "headline": "Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year"
              },
              {
                "id": 140809717,
                "url": "https://finnhub.io/api/news?id=0b887c1c3a57dcb3dbfc0bad12474feac5feee8d09492eb3cc296408add23f4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ulcerative colitis. The company announced new FDA approvals for KEYTRUDA-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer. Regulatory authorities in the EU also cleared additional KEYTRUDA combinations in early-stage oncology settings. For investors tracking NYSE:MRK, these updates sit at the core of what drives long term value for a...",
                "category": "company",
                "datetime": 1783206585,
                "headline": "Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test"
              },
              {
                "id": 140800044,
                "url": "https://finnhub.io/api/news?id=6a64d2682b456ce39b982ce5c7ed3f119bd9b7219dd3dc983948bba84dd903d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.",
                "category": "company",
                "datetime": 1783092855,
                "headline": "Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140801112,
                "url": "https://finnhub.io/api/news?id=5d0fcbac5cc5b764db3a7a66357d599a00971ea60c0776def7e158542f3aa154",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.",
                "category": "company",
                "datetime": 1783092720,
                "headline": "MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?"
              },
              {
                "id": 140798353,
                "url": "https://finnhub.io/api/news?id=af3ce6803222543543796d3613fb7b8ebe9f7614e6f6a9734ddef35d29886348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Antidiabetic Drugs Market size & share revenue was valued at approximately USD 103.21 Billion in 2025 and is expected to reach USD 115.02 Billion in 2026 and is expected to reach around USD 309.84 Billion by 2035, at a CAGR of 11.62% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Eli Lilly and Company,",
                "category": "company",
                "datetime": 1783067400,
                "headline": "[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140794037,
                "url": "https://finnhub.io/api/news?id=d34b320aa80113fce02e54c7d0e2a3e9dd50198bf09c66427dc6a9583845cac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State",
                "category": "company",
                "datetime": 1783020874,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140794032,
                "url": "https://finnhub.io/api/news?id=f4b49dc8a4155423aba64d44bfeefe3141a39ead48c7fb63d3305a6de9a47c89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.",
                "category": "company",
                "datetime": 1783015478,
                "headline": "Merck Stock, JPMorgan And Two Others Hit New Highs"
              },
              {
                "id": 140795133,
                "url": "https://finnhub.io/api/news?id=52987caaba1d0a4214a3d3520e4a63c4492060fd2ae8de73a16ba58c60747c14",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore this week’s dividend updates.",
                "category": "company",
                "datetime": 1783015043,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 5"
              },
              {
                "id": 140792979,
                "url": "https://finnhub.io/api/news?id=e3abb4735d28fe1ce35ae74f2a97593a9c387c3bc2375ef13f3b1e09dbb5d3b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S",
                "category": "company",
                "datetime": 1783014167,
                "headline": "Sector Update: Healthcare Stocks Gain Thursday Afternoon"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140793732,
                "url": "https://finnhub.io/api/news?id=02d33b3c3c02f1c3de9c4f770927cb1f940697516e24678c4d052b42bf8c0196",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268780783/image_2268780783.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. analysis: fairly valued after YTD rally as Keytruda & Winrevair lift guidance. Click for this updated look at MRK and see if it is right for you.",
                "category": "company",
                "datetime": 1783005739,
                "headline": "Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up"
              },
              {
                "id": 140800595,
                "url": "https://finnhub.io/api/news?id=d496e3fa576899848e38d53aa49bd5f7bcaf860c9b143f35ea2324fecbf3ac1c",
                "image": "https://image.cnbcfm.com/api/v1/image/108330186-1783019122904-1783018967-46914473154-hd.jpg?v=1783019124&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Jeff Kilburg, founder and CEO of KKM Financial, joins \"Power Lunch\" to discuss the growing interest in healthcare stocks.",
                "category": "company",
                "datetime": 1783004742,
                "headline": "KKM's Jeff Kilburg explains the healthcare trade in the second half of 2026"
              },
              {
                "id": 140785879,
                "url": "https://finnhub.io/api/news?id=68140cf16a5d7028256e4f2b2dcbd36c46c874bb868a7c0962444eafa0a1e070",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck cited business reasons for the discontinuation of the investigational drug.",
                "category": "company",
                "datetime": 1782943304,
                "headline": "MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership"
              },
              {
                "id": 140792449,
                "url": "https://finnhub.io/api/news?id=61b321aff28d9e37c54b5110047f1cec1b326ca8b0f5ed7545a9e24fa3530c17",
                "image": "https://image.cnbcfm.com/api/v1/image/108329655-4ED3-MM-D-BLOCK-070126.jpg?v=1782947477&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.",
                "category": "company",
                "datetime": 1782934819,
                "headline": "Moderna's now got a lot going for it, says Jim Cramer"
              },
              {
                "id": 140783353,
                "url": "https://finnhub.io/api/news?id=8d8d4dbcd75e54bc1136dbce779a2713eac74a23a63c39b81cb0c347fdd45387",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1782933003,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 140792450,
                "url": "https://finnhub.io/api/news?id=b96976863ba687c527e49a3f43a3026e48124bf4d995f19dca177bd6671423b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108000894-1771434677666-108000894-1719932078582-gettyimages-2151784856-MODERNA_RSV_VACCINE.jpg?v=1771437699&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis.",
                "category": "company",
                "datetime": 1782931819,
                "headline": "Jim Cramer says this former Covid market darling is finally investable again"
              },
              {
                "id": 140778779,
                "url": "https://finnhub.io/api/news?id=8450ad65d118343e8b422f14c5f3604af12f7054f08f4f6feb9b5a358c47f318",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?",
                "category": "company",
                "datetime": 1782906601,
                "headline": "Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140778806,
                "url": "https://finnhub.io/api/news?id=e6d11565509c7fc0723e438a4219e8df330054a0e47e77f2a719d7c7e7e10306",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 01, 2026--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4",
                "category": "company",
                "datetime": 1782902700,
                "headline": "Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4"
              },
              {
                "id": 140776953,
                "url": "https://finnhub.io/api/news?id=61b39c4de285b126d1370ef4287e5453adabfc0c48b650c80cb7a80df194c9f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Association for the Accreditation of Human Research Protection Programs has awarded full accreditation to five more entities, including the U.S. health professions academy and one of the world's leading pharmaceutical companies. The newly accredited entities are:",
                "category": "company",
                "datetime": 1782875400,
                "headline": "AAHRPP Accredits Five More Research Entities"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140774512,
                "url": "https://finnhub.io/api/news?id=60d4e872b38b8a51020c9e003ba137fc0486811d85f7026d6e974ba19d46aa88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%",
                "category": "company",
                "datetime": 1782848500,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 140775621,
                "url": "https://finnhub.io/api/news?id=ba4bee7973b33d1ab47b1c5bd0bd439d3450cca266c881f93fcb051a7eb2bf2d",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782842568,
                "headline": "Verizon Leads July's 'Safer' Dogs Of The Dow; Nike Near 'Ideal'"
              },
              {
                "id": 140781615,
                "url": "https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db",
                "image": "https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.",
                "category": "company",
                "datetime": 1782841349,
                "headline": "Anthropic launches Claude Science"
              },
              {
                "id": 140773529,
                "url": "https://finnhub.io/api/news?id=91b4ae92589b2d9ea19e8b779447047ca848480cd0fa312ab704a6fb7f0dab03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. lawmakers have opened national security investigations into Merck's clinical trial activities in China. The probes focus on trials conducted in politically sensitive regions, including Xinjiang, and at hospitals linked to the Chinese military. Key concerns include intellectual property protection, ethical oversight, and the handling of sensitive biotechnology data. Merck, listed as NYSE:MRK, is a large global pharmaceutical company with a heavy focus on prescription medicines,...",
                "category": "company",
                "datetime": 1782839197,
                "headline": "Merck (MRK) Faces U.S. Security Probe Over China Clinical Trials"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140772851,
                "url": "https://finnhub.io/api/news?id=7831567aa0ddc4cfcc09a725c5a9c933c5dc83303d23c0b0f4f928d6a5657a5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's (MRK) upcoming phase 3 OptiTrop-Lung06 readout could establish SAC-TMT as a chemotherapy rep",
                "category": "company",
                "datetime": 1782832053,
                "headline": "Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says"
              },
              {
                "id": 140775064,
                "url": "https://finnhub.io/api/news?id=02108edcb5c3c19ddb4166472d2697a0109d53eddc73f4cf08f9c2cf976cda9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "B of A Securities  analyst Tim Anderson   maintains Merck &amp; Co (NYSE:MRK) with a Buy and raises the price target from $130 to $141.",
                "category": "company",
                "datetime": 1782826795,
                "headline": "B of A Securities Maintains Buy on Merck & Co, Raises Price Target to $141"
              },
              {
                "id": 140781677,
                "url": "https://finnhub.io/api/news?id=ab65f7a3201d95ef11cd96835570ff682d86a3d9510e670ecc990714c0d3509f",
                "image": "https://image.cnbcfm.com/api/v1/image/108264191-1770764453454-gettyimages-2259521349-img_7851.jpeg?v=1770764487&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782825385,
                "headline": "Stocks making the biggest moves midday: AeroVironment, Abivax, Astera Labs, Watts Water Technologies & more"
              },
              {
                "id": 140771981,
                "url": "https://finnhub.io/api/news?id=1b0f26a15d0484950f3723cd1a9eeaeda916aa55b962ae7710464a962924f4e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang",
                "category": "company",
                "datetime": 1782824140,
                "headline": "Merck, AbbVie investigated over China military hospital drug trials"
              },
              {
                "id": 140772002,
                "url": "https://finnhub.io/api/news?id=50be84fb33f2632af8f65895891eccf8c50463a9cb8fe133ab23138261a1c821",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?",
                "category": "company",
                "datetime": 1782821103,
                "headline": "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140771584,
                "url": "https://finnhub.io/api/news?id=6c754633791e8e46d89dc976069416ae410eb3a21e59837ad76cd1b1e0936bb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US Hous",
                "category": "company",
                "datetime": 1782819184,
                "headline": "Market Chatter: AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China"
              },
              {
                "id": 140775065,
                "url": "https://finnhub.io/api/news?id=27789a54ddee9badae264cf469a6b54f0adbbb7ec05dc6b2a6315c1daa71b429",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Scotiabank  analyst Louise Chen   maintains Merck &amp; Co (NYSE:MRK) with a Sector Outperform and raises the price target from $136 to $155.",
                "category": "company",
                "datetime": 1782816597,
                "headline": "Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $155"
              },
              {
                "id": 140781710,
                "url": "https://finnhub.io/api/news?id=3df3441b99c591d54c3f5c8a360b236c02f57bee97df464f2bc66c2ef6f772a3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328691-3ED1-REQ-063026-NewsOPEN.jpg?v=1782827583&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1782813641,
                "headline": "Market Open: June 30, 2026"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140772369,
                "url": "https://finnhub.io/api/news?id=e00ce0091248ea12ffc6edc03cf742025d4e18a34a9a0f800f183d3a3e993f4c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials conducted in China.",
                "category": "company",
                "datetime": 1782810790,
                "headline": "Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report"
              },
              {
                "id": 140781711,
                "url": "https://finnhub.io/api/news?id=02d91ccebaaebf5085bf9b485c8b12d7b5bd1bd29f0076b7a6472ba09dd6d4c7",
                "image": "https://image.cnbcfm.com/api/v1/image/107384812-1709909242625-gettyimages-1124366588-20190212-dm-gtyworldagexpo-05.jpeg?v=1751374629&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1782804461,
                "headline": "Stocks making the biggest moves premarket: AeroVironment, Strategy, Merck & more"
              },
              {
                "id": 139930306,
                "url": "https://finnhub.io/api/news?id=7c7bc27315adbe5bcfe5ed5e35cd4e6dcc9d016797069c983e56b5235fa1d71d",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782799815,
                "headline": "How Your Taxes Will Be Different Next Year, And Why You'll Have Trump To Thank"
              },
              {
                "id": 140781757,
                "url": "https://finnhub.io/api/news?id=5baed29654721b5d98fe3ce501ae03081ebb89e584dc62b245c3de70b534c11e",
                "image": "https://image.cnbcfm.com/api/v1/image/108262197-1770323920909-gettyimages-2260105869-bb1_2632_uxvikxrq.jpeg?v=1782775477&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "The Dow rose more than 300 points on Monday to post its first close above 52,000. Alphabet, a new addition to the 30-stock index, jumped almost 5%.",
                "category": "company",
                "datetime": 1782760725,
                "headline": "Tuesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140765416,
                "url": "https://finnhub.io/api/news?id=95a85c6616a1501f68624ef59ae95118582b4bae62be2a70cc74e23ab2cfc456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.",
                "category": "company",
                "datetime": 1782758026,
                "headline": "AbbVie Stock Rockets 17% With 5-Day Winning Streak"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140765446,
                "url": "https://finnhub.io/api/news?id=d9ce9227f83812c8375c292a2411e4b04a0dca1e07fcfea1c6517855e3ae1b31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.",
                "category": "company",
                "datetime": 1782752520,
                "headline": "MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines"
              },
              {
                "id": 140762604,
                "url": "https://finnhub.io/api/news?id=2721bf0ff4ee829f4aadac8e52d2a889b76b2f9c38ae921e9e650d42dd5dedc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1782739806,
                "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?"
              },
              {
                "id": 140763353,
                "url": "https://finnhub.io/api/news?id=1f7f419f3bbad927aef061ca6d26d67e1cd18b1b1b987034a5656bdefd9c12f3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328213-17827514121782751407-46849797479-1080pnbcnews.jpg?v=1782751411&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's \"Halftime Report\" team debate the end of the quarter and discuss their trading strategy heading into the second half of the year.",
                "category": "company",
                "datetime": 1782738106,
                "headline": "'Halftime' traders debate the market setup for the next half of 2026"
              },
              {
                "id": 140761605,
                "url": "https://finnhub.io/api/news?id=711bbcaa4e6c6f8f4def15798e9b51c879c48983f3b74c54917a4d6ed5a4b9bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782735720,
                "headline": "Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?"
              },
              {
                "id": 140761567,
                "url": "https://finnhub.io/api/news?id=e4fd842930c69b4cb1219cad2efac884044ac9b9e4bb65154af4b5903dc71e21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1782733560,
                "headline": "Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?"
              },
              {
                "id": 140760729,
                "url": "https://finnhub.io/api/news?id=300b30523bfcd6ad0bb54ec19ad0bfcca200e7c34eba942e0c0d2964684a429b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Nasdaq 100 futures advanced more than 1% in premarket trade after tech stocks shed nearly 5% last week",
                "category": "company",
                "datetime": 1782732787,
                "headline": "S&P 500 Nasdaq futures rise after U.S.-Iran pause June 2026"
              },
              {
                "id": 140760836,
                "url": "https://finnhub.io/api/news?id=552695bf793ba252b3b2ca8b51026f1fce9a3dffdba15c9f7207092b1de227e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 29, 2026--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.",
                "category": "company",
                "datetime": 1782729900,
                "headline": "Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV"
              },
              {
                "id": 140762948,
                "url": "https://finnhub.io/api/news?id=d5667ff3dc444911aa93f22458176bb0017d39392aa80bfb4a7b359fdca46bed",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligible individualsMerck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced an agreement",
                "category": "company",
                "datetime": 1782715664,
                "headline": "Merck Agrees With ADAP Crisis Task Force To Help State AIDS Drug Assistance Programs Provide Access To Once-Daily HIV Treatment, IDVYNSO"
              },
              {
                "id": 140763428,
                "url": "https://finnhub.io/api/news?id=92a429b37c231d9f5231f399145e88c19987d9fbc67df37ba0a7d7744eb5e2a8",
                "image": "https://image.cnbcfm.com/api/v1/image/108326264-17823199802026-06-24t160038z_1026825060_rc2d0mafrueq_rtrmadp_0_usa-stocks.jpeg?v=1782320413&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Stocks rose Monday as investors weighed a pause in hostilities between the U.S. and Iran.",
                "category": "company",
                "datetime": 1782669838,
                "headline": "Dow jumps more than 200 points as U.S.-Iran halt hostilities, Alphabet shares gain: Live updates "
              },
              {
                "id": 140753990,
                "url": "https://finnhub.io/api/news?id=fce43d52df7f57adcf19b0141f93fe4ff31409260163bd796f09da38fba70f7a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2264471660/image_2264471660.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Schwab US Dividend Equity ETF offers mature, profitable businesses at a blended P/E of 15.6x, a significant discount to the S&P 500. Click for more on SCHD.",
                "category": "company",
                "datetime": 1782639000,
                "headline": "It's Time To Go All-In On SCHD"
              },
              {
                "id": 140750602,
                "url": "https://finnhub.io/api/news?id=f27f6b207bda2bcdc279e668a6badafa286297ecc1fd4ccaff83dd1b21071abd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]",
                "category": "company",
                "datetime": 1782605263,
                "headline": "Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC"
              },
              {
                "id": 140741514,
                "url": "https://finnhub.io/api/news?id=a9b2ccd9c36d16b4a7fae37b8185475d6136f42de99ad8853ea71a7729216c1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Wondering whether Merck at US$128.66 is still offering fair value, or if the recent run means you are paying too much for the stock? The share price moves have been strong, with Merck showing returns of 13.0% over 7 days, 7.0% over 30 days, 20.9% year to date and 68.1% over the past year, in addition to longer term returns of 22.3% over 3 years and 91.3% over 5 years. Recent headlines around Merck have kept the stock in focus and reinforced investor attention on its long term prospects and...",
                "category": "company",
                "datetime": 1782511739,
                "headline": "Merck (MRK) Stock Weighs Strong Rally Against Mixed Valuation Signals"
              },
              {
                "id": 140741515,
                "url": "https://finnhub.io/api/news?id=8d9644330c3b8a7b4423042e3f8abe71673405c6d3704294d62da69c3d399984",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session.",
                "category": "company",
                "datetime": 1782510304,
                "headline": "Merck (MRK) Gains As Market Dips: What You Should Know"
              },
              {
                "id": 140746824,
                "url": "https://finnhub.io/api/news?id=831a4124991b2786a798864184e8fb4efcc4b4b5c724b52fafff675365e108f1",
                "image": "https://image.cnbcfm.com/api/v1/image/108327759-17825112941782511292-46793441687-1080pnbcnews.jpg?v=1782511293&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC’s “Fast Money” team shares their final trades of the day.",
                "category": "company",
                "datetime": 1782497183,
                "headline": "Final Trade: GM, XLV, MRK, SPCX"
              },
              {
                "id": 140737991,
                "url": "https://finnhub.io/api/news?id=4f1f92e9bfd556033ca1e9a7a947069be8194bd99d29c4f03bd80a254adeb6e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Lilly, AbbVie and J&J extend winning streaks.",
                "category": "company",
                "datetime": 1782496164,
                "headline": "Lilly, J&J and AbbVie Hit New Highs"
              },
              {
                "id": 140741516,
                "url": "https://finnhub.io/api/news?id=c52d398d2b5710d0f99c0173129e8151ad7aead20b89218f39213d283f70ec62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?",
                "category": "company",
                "datetime": 1782494910,
                "headline": "The $11 Billion Reason TECH Stock Is Up Today"
              },
              {
                "id": 140746796,
                "url": "https://finnhub.io/api/news?id=fe15595f4953f27cc4b58c74d5c83ff2d2864a24e30ace17bb82dd2bdc1827df",
                "image": "https://image.cnbcfm.com/api/v1/image/108327725-17825072231782507209-46792477115-1080pnbcnews.jpg?v=1782507222&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.",
                "category": "company",
                "datetime": 1782493286,
                "headline": "Why BMO's Siegerman says Merck is a top healthcare stock pick"
              },
              {
                "id": 140737993,
                "url": "https://finnhub.io/api/news?id=4ec7a0224ab0405979874fb3b438152890cd9bb8fada3b210159c9b7b2acaaad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.",
                "category": "company",
                "datetime": 1782489808,
                "headline": "AbbVie Stock's Growth Story Has One Question Mark"
              },
              {
                "id": 140738042,
                "url": "https://finnhub.io/api/news?id=f8b316ddbf026bf067b5337eb62e61e0db952dee0b18064b45a8553ecf61881b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?",
                "category": "company",
                "datetime": 1782489673,
                "headline": "Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?"
              },
              {
                "id": 140738319,
                "url": "https://finnhub.io/api/news?id=836bcfe7c2e7088a1d512d316d935002acddd7e4f3d6233f67bdf2745c49da75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160887573/image_1160887573.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Micron goes volatile on great news, SpaceX the bellwether and Fed interest rate commentary.",
                "category": "company",
                "datetime": 1782483240,
                "headline": "Wall Street Roundup: What Isn't Priced In?"
              },
              {
                "id": 140738484,
                "url": "https://finnhub.io/api/news?id=ef5060389f60276f62729917f5f1870ad05f242bbb0eaf9b66b4ccc315ed7ca7",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.cdc.gov/ebola/situation-summary/index.html",
                "category": "company",
                "datetime": 1782479453,
                "headline": "CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low"
              },
              {
                "id": 140736489,
                "url": "https://finnhub.io/api/news?id=ef5d826f2613b98deb5161d09e1d52995b18f500b121370048657125da8de6cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1782478806,
                "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140736490,
                "url": "https://finnhub.io/api/news?id=da3c5fb9cd6fcd9972234207c964aa1996e4a20ce9d71fbece3028444dd6b146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782478800,
                "headline": "Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?"
              },
              {
                "id": 140734602,
                "url": "https://finnhub.io/api/news?id=75a2245510d373a6d6c50defb3e2c0bb9b28a68cf403c213f8026e5b42c2364d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]",
                "category": "company",
                "datetime": 1782472268,
                "headline": "Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results"
              },
              {
                "id": 140735129,
                "url": "https://finnhub.io/api/news?id=8f1bf596ce182e56e350eee0da5f22dee126d24c8d2f65b0f0da933c699ddae7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260722103/image_2260722103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Jazz Pharmaceuticals' shares are in the distribution phase because Zepzelca failed to show a survival benefit over irinotecan. See why JAZZ stock is downgraded to hold.",
                "category": "company",
                "datetime": 1782465751,
                "headline": "Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)"
              },
              {
                "id": 140736177,
                "url": "https://finnhub.io/api/news?id=70ba6349f55e6c169bedab13e6f19866634ca1540b8b3e27a10416cb9ab8f55b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/26/Qualcomm.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Jim Lebenthal suggests investing in Qualcomm on CNBC&#39;s Halftime Report, while Stephanie Link chose Rockwell Automation.",
                "category": "company",
                "datetime": 1782459159,
                "headline": "Qualcomm, Merck, Rockwell Automation And A Real Estate Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 140738043,
                "url": "https://finnhub.io/api/news?id=a91060899654895f2c29f9a74f86e0fbe5dd804cdb74c4c8577009e830fed0e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.",
                "category": "company",
                "datetime": 1782446460,
                "headline": "Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal"
              },
              {
                "id": 140732215,
                "url": "https://finnhub.io/api/news?id=1011afe06ab0dcb1ee22df6c23045e72aa8b02ac4e24a7896a5b564ca2bb6f22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]",
                "category": "company",
                "datetime": 1782443886,
                "headline": "Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger"
              },
              {
                "id": 140729450,
                "url": "https://finnhub.io/api/news?id=adb40a383a2e09f0f626b3f872c4ce91a962c239c4a12c08f8da43c1f3995ea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises. Mr. Sims will lead the commercial strategy and […] The post Candel Therapeutics Designates Mark Sims as CCO appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1782417238,
                "headline": "Candel Therapeutics Designates Mark Sims as CCO"
              },
              {
                "id": 140728307,
                "url": "https://finnhub.io/api/news?id=6156b9c7e94fbc96f2c772f6ca588b01f30909829d24a93ad278d456696ed7ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).",
                "category": "company",
                "datetime": 1782414935,
                "headline": "Big Tech stocks tumble while Micron continues to gain on Q3 earnings"
              },
              {
                "id": 140729452,
                "url": "https://finnhub.io/api/news?id=13b5af933eca7bd4760ac13e68e51ca50be6bc0cf7e898fba0d439162a3770b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of  Bio-Techne  surged Thursday after Germany’s  Merck KGaA  announced it agreed to purchase the company for $11.3 billion.  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the  for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.  Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.",
                "category": "company",
                "datetime": 1782414720,
                "headline": "Bio-Techne Is a Top S&P 500 Stock. Germany’s Merck Is Paying a 24% Premium for the Company."
              },
              {
                "id": 140728193,
                "url": "https://finnhub.io/api/news?id=8812f369e1c746da48a498d89ecec0b3727d6002df6251389f0d5edede169eb4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1782414604,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 140728429,
                "url": "https://finnhub.io/api/news?id=5b587aba6b3e9cd920adca306a24a5151cd34ebe0ef214f66040c931402b6234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective.",
                "category": "company",
                "datetime": 1782414000,
                "headline": "Alger Russell Innovation Index Updates for Second Quarter 2026"
              },
              {
                "id": 140726156,
                "url": "https://finnhub.io/api/news?id=6b6ac7dc515d60883d5ed0e2ae4b17ad9689a83d2763c59fd758ba8dd4810dfe",
                "image": "",
                "source": "Fintel",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782404866,
                "headline": "CICC Initiates Coverage of Merck (MRK) with Outperform Recommendation"
              },
              {
                "id": 140725573,
                "url": "https://finnhub.io/api/news?id=80e91ccc77cd3a7657c698a7e1f0f4a3aae504e29025f6ea0f407e423646f060",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nas",
                "category": "company",
                "datetime": 1782402056,
                "headline": "Top Midday Stories: Micron Shares Soar After Estimate-Topping Earnings Results; Bio-Techne to be Acquired by Merck for $11.3 Billion"
              },
              {
                "id": 140727299,
                "url": "https://finnhub.io/api/news?id=c475adbeccd67d5849385444c6edbf827f5552c084194728e669f22c32033269",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The S&P 500 index was up about 0.3%, while the Nasdaq Composite fell 0.4%.",
                "category": "company",
                "datetime": 1782400321,
                "headline": "Dow Soars Over 750 Points, Hits Record High As Investors Look Beyond Tech Stocks — PCE Inflation Comes In Hottest Since October 2023"
              },
              {
                "id": 140725717,
                "url": "https://finnhub.io/api/news?id=9ba5a4e89ab45507420ec3554c35e1301000068556095a6539f53d642de20357",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of  Bio-Techne  surged Thursday after Germany’s  Merck KGaA  announced it agreed to purchase the company for $11.3 billion.  Bio-Techne stock jumped 19% to $70.25 on Thursday, leading the  for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.  Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.",
                "category": "company",
                "datetime": 1782397800,
                "headline": "Bio-Techne Is Today’s Top S&P 500 Stock. Germany’s Merck Is Paying a 24% Premium for the Company."
              },
              {
                "id": 140725718,
                "url": "https://finnhub.io/api/news?id=c169edde559d1849c06624b07afcaf68caadaaf32779f39fe99cf79577c5bb82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.",
                "category": "company",
                "datetime": 1782397344,
                "headline": "Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion"
              },
              {
                "id": 140725719,
                "url": "https://finnhub.io/api/news?id=219e37537f2ba78d10f1c40efee004ae81a92833455fb224483337b6e48b659d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.",
                "category": "company",
                "datetime": 1782397140,
                "headline": "Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use"
              },
              {
                "id": 140725720,
                "url": "https://finnhub.io/api/news?id=a346fb06878946df84b361ac6cf8e147819535aaa49b566713e29cf2e293446c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.",
                "category": "company",
                "datetime": 1782396240,
                "headline": "MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer"
              },
              {
                "id": 140726733,
                "url": "https://finnhub.io/api/news?id=cbef7ca64e81f74d3e6a7982fb09e629469de23e7a6c3b7965d6951cf5e76dd0",
                "image": "https://image.cnbcfm.com/api/v1/image/108326946-17824069151782406912-46768080827-1080pnbcnews.jpg?v=1782406913&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "The Investment Committee give you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1782393530,
                "headline": "Final Trades: Qualcomm, Rockwell Automation, Merck and Simon Property Group"
              },
              {
                "id": 140724627,
                "url": "https://finnhub.io/api/news?id=b9fbde41b210d86c06c3b17cb5bc6f9ee435d1fe6a80d089b018599fc63f167f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bio-Techne (TECH) said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with",
                "category": "company",
                "datetime": 1782392828,
                "headline": "Bio-Techne to Be Acquired by Germany's Merck in $11.3 Billion Deal"
              },
              {
                "id": 139939358,
                "url": "https://finnhub.io/api/news?id=4f94d0fc9b1e70b1626ced271fdf34107fd56fba4b23b4c8fcf9095715ba0041",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782392476,
                "headline": "Live On CNBC, Josh Brown Hosts Segment Titled \"Josh's Best Stocks In The Market: Realty Income, Prologis, Simon Property Group\""
              },
              {
                "id": 140724628,
                "url": "https://finnhub.io/api/news?id=e60e0d53c29cae6a62405f595805fcb0a85ab2d24a77ac35334cdf053e7f339c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]",
                "category": "company",
                "datetime": 1782392426,
                "headline": "REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan"
              },
              {
                "id": 140726459,
                "url": "https://finnhub.io/api/news?id=4fa9ca3330c85c052ac4f2e969e64ca7758fe558d2fc9f2c84ad2ebc4f869d4c",
                "image": "https://image.cnbcfm.com/api/v1/image/108318383-1780944003656-gettyimages-2279919808-AFP_B6EK9TC.jpeg?v=1780944021&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1782390956,
                "headline": "Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more"
              },
              {
                "id": 140723919,
                "url": "https://finnhub.io/api/news?id=a810afe55ccc6d991d4828e65543a28b9526212c51ef121db6a7d0e83b1a9458",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of  Bio-Techne  surged before the opening bell on Thursday after Germany’s  Merck KGaA  announced it has agreed to purchase the company for $11.3 billion.  Bio-Techne stock jumped 21% to $70.95 in premarket trading on Thursday.  Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.",
                "category": "company",
                "datetime": 1782386280,
                "headline": "Germany’s Merck Is Buying Bio-Techne for $11.3 Billion"
              },
              {
                "id": 140729091,
                "url": "https://finnhub.io/api/news?id=e6863c9b865e6d27fdd72299cdce3221d0c00cfd208260a97a53c1500d7ef9c7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/25/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "FDA approves Gilead&#39;s Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.",
                "category": "company",
                "datetime": 1782386249,
                "headline": "Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer"
              },
              {
                "id": 140723920,
                "url": "https://finnhub.io/api/news?id=69d685115c1ba21a4dd0a640667438bb963b850e74e2a79d8fdd0507bbe4fda8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Germany’s Merck KGaA has announced a major acquisition agreement to buy U. S.",
                "category": "company",
                "datetime": 1782385056,
                "headline": "Germany’s Merck to Acquire Bio-Techne in $11.3 Billion Deal"
              },
              {
                "id": 140723921,
                "url": "https://finnhub.io/api/news?id=88e6dc07477e86c158a86650fd8f8b1f85cf071d8d7e26a7715ee71d886b9659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 25, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative br",
                "category": "company",
                "datetime": 1782384300,
                "headline": "FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)"
              },
              {
                "id": 140723922,
                "url": "https://finnhub.io/api/news?id=4c2ea899e14e67216e9444d62f90d53511b2c7824a476b3136cdedf1546d4a27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36%",
                "category": "company",
                "datetime": 1782382200,
                "headline": "Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets"
              },
              {
                "id": 140724629,
                "url": "https://finnhub.io/api/news?id=242b474ec3540cb65ce22afb0d9e3063b0e235fb9bfea18c6dbe0a8f1f0c4462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA offered $73 a share in cash for Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.",
                "category": "company",
                "datetime": 1782382080,
                "headline": "Germany’s Merck to Buy Bio-Techne for $11 Billion"
              },
              {
                "id": 140724395,
                "url": "https://finnhub.io/api/news?id=4103ee9f0605d35d70f4749bf7d87232b08923f7eebce92623e47d35efaab78e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "GSK stock outlook: 3.46% dividend yield, 2026 core EPS growth guided at 7%–9%, and Exdensur as a new asthma growth driver—read the analysis now.",
                "category": "company",
                "datetime": 1782380178,
                "headline": "Is GSK Quietly Becoming An Oncology Powerhouse"
              },
              {
                "id": 140729092,
                "url": "https://finnhub.io/api/news?id=f72373c2d773fedf4214119cbb683f48a34a1d32c25101ff61937fa9cd30ac7c",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s",
                "category": "company",
                "datetime": 1782370449,
                "headline": "Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For First-Line Treatment Of Breast Cancer"
              },
              {
                "id": 140721998,
                "url": "https://finnhub.io/api/news?id=1bb1ba6a3d41e7dd288a8668e75ab383ebe6cd18b53636aeb910f35a725a4618",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 24, CICC initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating. It also set a $138 price target on the stock. Merck also provided an updated outlook during its first-quarter 2026 earnings call. […]",
                "category": "company",
                "datetime": 1782360518,
                "headline": "Merck (MRK) Stock Gets New Outperform Rating from CICC"
              },
              {
                "id": 140720797,
                "url": "https://finnhub.io/api/news?id=01dcfc8bf1f4b5374b14db8fd69d8059083f76ef475afca19bdb76d377095ff4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1449224970/image_1449224970.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "TCW Relative Value Large Cap Fund reports Q1 2026 performance and portfolio adjustments. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1782338700,
                "headline": "TCW Relative Value Large Cap Fund Q1 2026 Buys And Sells"
              },
              {
                "id": 140717005,
                "url": "https://finnhub.io/api/news?id=3f59a4c983b77042aa9b5c7b418ca5680832404b8328b939e755f4f4f4ef0e61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.",
                "category": "company",
                "datetime": 1782329550,
                "headline": "The Number That Could Test AbbVie Stock"
              },
              {
                "id": 140717060,
                "url": "https://finnhub.io/api/news?id=cf21eca9e56a27152b8fdb4d406b3ea9702f039e8f48562f3f9c7d336228c57f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a collaboration with global pharmaceutical leader MSD (Merck & Co., Inc., Rahway, New Jersey, USA) to explore the feasibility of establishing a logistics hub in Abu Dhabi's Health, Endurance, Longevity, and Medicine (HELM) Cluster.",
                "category": "company",
                "datetime": 1782328500,
                "headline": "Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region"
              },
              {
                "id": 140716596,
                "url": "https://finnhub.io/api/news?id=913f41419cf207e070247f93f2e5c79a4c26c31d243a3316ddb8b0588887e264",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1782328203,
                "headline": "Wednesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 140715774,
                "url": "https://finnhub.io/api/news?id=b07b02658f5a1f627052bfdb8759128764dafe5a59adefdee020787600cd0033",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Density Gradient Media Market size & share revenue was valued at approximately USD 1.8 Billion in 2025 and is expected to reach USD 2 Billion in 2026 and is expected to reach around USD 5.3 Billion by 2035, at a CAGR of 11.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are GE Healthcare, Avantor Inc., ST",
                "category": "company",
                "datetime": 1782318600,
                "headline": "[Latest] Global Density Gradient Media Market Size/Share Worth USD 5.3 Billion by 2035 at a 11.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140715775,
                "url": "https://finnhub.io/api/news?id=131da7ac3242697939938400e8f3940e8625d88d13ca92411370d6ffe94c43c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.",
                "category": "company",
                "datetime": 1782314700,
                "headline": "Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC"
              },
              {
                "id": 140716350,
                "url": "https://finnhub.io/api/news?id=e91ff26077647b880e9d4dc41410cfc51f6b69b1332551a5ea8c2874d885cbb4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2281769390/image_2281769390.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "MacroGenics, Inc. downgraded to Hold after B7-H3 ADC setbacks; assess MGC026 phase 1 catalysts, pipeline risks, and liquidity outlook—click for this MGNX update.",
                "category": "company",
                "datetime": 1782311719,
                "headline": "MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment"
              },
              {
                "id": 140712894,
                "url": "https://finnhub.io/api/news?id=dff7ed81f12349a3014c0f3871606dd9362851f7a566bded7bfdb846b6bc376a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Merck & Co., Inc. (NYSE:MRK) is one of the best weight loss drugs on this list. TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its […]",
                "category": "company",
                "datetime": 1782307612,
                "headline": "Is Merck & Co., Inc. (MRK) Strengthening Its Vaccine Portfolio With New Capvaxive Approval?"
              },
              {
                "id": 140712895,
                "url": "https://finnhub.io/api/news?id=af7dd1698707345a87c9e7febb0f8a711fd45f922d4e4112936860d0382df7a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When ... Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Soft",
                "category": "company",
                "datetime": 1782303312,
                "headline": "Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More"
              },
              {
                "id": 140712211,
                "url": "https://finnhub.io/api/news?id=9ccc165297edd2622175778ed2c20535a5698d0aadc4dd3ef569f70fda7036ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 24, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), an antibody-drug conjugate (ADC), is approved in the European Union (EU), as neoadjuvant treatment and then continued after radical cystectomy (RC) as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin",
                "category": "company",
                "datetime": 1782297900,
                "headline": "European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer"
              },
              {
                "id": 140713702,
                "url": "https://finnhub.io/api/news?id=6903272a95031a3d5908c8d7f528a7ac331d3b7e6670ac3158181b2268c24815",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "This approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in collaboration with Pfizer and Astellas. In the study, KEYTRUDA plus Padcev, as perioperative",
                "category": "company",
                "datetime": 1782283685,
                "headline": "The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy"
              },
              {
                "id": 140707021,
                "url": "https://finnhub.io/api/news?id=a7a3d34f7810f7671686594b7ea4a20fe6d754140bd2b6fd7e9af81ef6290fe4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In June 2026, Merck reported positive Phase 3 results for its anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis, alongside recent US FDA approvals expanding KEYTRUDA–WELIREG use in kidney cancer and CAPVAXIVE’s indication to higher-risk children and adolescents. Together, these updates highlight Merck’s push to broaden its portfolio beyond oncology by advancing late-stage immunology assets and deepening its vaccines and cancer franchises. We’ll now examine...",
                "category": "company",
                "datetime": 1782249397,
                "headline": "How New Immunology and Vaccine Milestones At Merck (MRK) Have Changed Its Investment Story"
              },
              {
                "id": 140706976,
                "url": "https://finnhub.io/api/news?id=40cea8fb275d861a3becf0bae0ceea497224f2f0a3b6e14fb3a81a0e9b67bd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.",
                "category": "company",
                "datetime": 1782244632,
                "headline": "The $50B Plan Merck Stock Was Broadcasting"
              },
              {
                "id": 140705613,
                "url": "https://finnhub.io/api/news?id=dacb874b40001fae147568e753562394b2ecc01221640017e808e3754fad2459",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St",
                "category": "company",
                "datetime": 1782243964,
                "headline": "Sector Update: Healthcare Stocks Higher Late Afternoon"
              },
              {
                "id": 140705639,
                "url": "https://finnhub.io/api/news?id=5dd36676d50cb28bd7056839a36f94b9a6b54c22b0b1215ccd6902bcad54e620",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]",
                "category": "company",
                "datetime": 1782243905,
                "headline": "Redditors Think Tempus AI (TEM) Still Has 10X Potential"
              },
              {
                "id": 140705640,
                "url": "https://finnhub.io/api/news?id=0a6352c273c67e6ccbdcd2d5f379f41b11f856473120992e47eb06a540d66eb5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.",
                "category": "company",
                "datetime": 1782239040,
                "headline": "EXEL Down on Colorectal Cancer Study Data on Zanzalintinib"
              },
              {
                "id": 140704308,
                "url": "https://finnhub.io/api/news?id=55b4e6d315e5163a4cefd9286875131ce7a1a2f6b4d0e11cf68c3a82a7a92293",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.",
                "category": "company",
                "datetime": 1782229440,
                "headline": "Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study"
              },
              {
                "id": 140702600,
                "url": "https://finnhub.io/api/news?id=921a44a81749b4ef06389737c07a72d28c2efcae097c4e44898d2ffd854a0bb0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.",
                "category": "company",
                "datetime": 1782221400,
                "headline": "Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC"
              },
              {
                "id": 140701463,
                "url": "https://finnhub.io/api/news?id=5ffde01b735041e405b0af509d73949b64902768dc154cb1e72c5aff1906f451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bank of America has predicted that the Federal Reserve will be forced to raise interest rates by 75 basis points this year, with the first 25-basis-point hike in September. They also see additional 25-basis-point hikes in October and December. The energy shock from the war with Iran drove inflation higher, with the CPI rising in ... Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants",
                "category": "company",
                "datetime": 1782218405,
                "headline": "Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants"
              },
              {
                "id": 140701432,
                "url": "https://finnhub.io/api/news?id=18f1e4cfd0598feca125bcf022d603484177055aad67802d5c5e9c2b913ef1ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.",
                "category": "company",
                "datetime": 1782217249,
                "headline": "Should You Buy Or Sell AbbVie Stock At $230?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 234,
            "discarded_article_count": 208
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 11747393.333333334,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 9366810,
              "avg_vol_20": 11380455,
              "avg_vol_30": 11747393.333333334,
              "range_pct_10": 0.09308689710610944,
              "range_pct_20": 0.1621383440514471,
              "range_pct_30": 0.1621383440514471,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7973522069293102,
              "dist_to_20d_high": 0.05571587553393996,
              "down_shrink_days": 4,
              "breakout_level_20d": 131.74001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5741201913137378
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.0460610932475882,
              "turnoverUsdM": 961.0768312,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRK",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 116.8214,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.1,
            "take_profit_price": 130.62,
            "target_multiplier": 1.6,
            "technical_strength": 1.22,
            "take_profit_percent": 5
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.0921221864951765,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.7893,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.05
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 10.84
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0899
    },
    "kdj": {
      "d": 43.73,
      "j": 49.49,
      "k": 45.65,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 40.97
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 6010102,
      "recentSlope": -2708339.8,
      "previousSlope": 4937580
    },
    "rsi": 42.27,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 129.5036,
      "position": "SAR喺價上",
      "distancePct": 4.1,
      "previousTrend": "下降"
    },
    "ma50": 119.7398,
    "macd": {
      "macd": 1.5971010675361157,
      "trend": "中性偏多",
      "signal": 1.938686782584484,
      "histogram": -0.3415857150483683
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 125.1696,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.75,
      "score": 2,
      "avgVolume": 10290660,
      "currentVolume": 7725698
    },
    "derived": {
      "ma20": 125.0395,
      "ma50": 119.7398,
      "prevClose": 127.5,
      "avgVolume10": 9189450,
      "avgVolume20": 10290660,
      "changePercent": -2.43,
      "avgVolumeForScore": 10290660
    },
    "ma_cross": {
      "ma20": 125.0395,
      "ma50": 119.7398,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 124.513,
      "prevMa50": 119.523,
      "spreadPct": 4.43,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 117.8218,
      "upper": 132.2572,
      "position": "中間"
    },
    "rsi_short": 53.11,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.75
    }
  }
}

{
  "close": 124.4,
  "volume": 7725698,
  "changePercent": -2.43
}